Impression Healthcare Limited (ASX: IHL) is an Australia registered company involved in manufacturing and marketing of home-impression custom-fit mouthguards. The company, by release, updated the market about inking of exclusive CBD product supply agreement with AXIM Biotechnologies for Periodontitis, which is at the forefront of cannabinoid research.
IHL communicated that the license and supply agreement is a precursor to the imminent beginning of the clinical trial related to CBD mouthwash and toothpaste for Periodontitis to be undertaken by the Swinburne University of Technology. AXIM will supply the first batch of toothpaste, mouthwash and associated placebo units needed for a randomised control clinical trial of around 40 participants. The company might exclusively supply the products on a commercial basis within Australia and New Zealand, to any person in line with the rules of the SAS, which has been outlined by the Therapeutic Goods Administration following the completion of the clinical trial.
AXIM is HQed in New York and is focused on development, research and production of nutraceutical, pharmaceutical, cosmetic and oral health products, which incorporates cannabinoids. It has established a full chain of production, including extraction, purification, conversion and microencapsulation.
Moreover, the company further pointed out that ~ 20% of the Australian population and around 40% of Australians aged 55 years or above had moderate-to-severe periodontitis, also recognised as Gum Disease. IHL will immediately begin the process to import the initial batch of products as soon as practicable in preparation for the clinical trial that will be directed by the Swinburne University of Technology.
In accordance with the previous announcement dated 21st March 2019, the company mentioned that the cost to IHL to conduct the trial has been capped at $80,000 along with the remaining costs, which is being funded by the Cannvalate and the Swinburne University of Technology.
In another announcement made on 21st May 2019, the company highlighted that it had lodged an application with the Federal Court of Australia seeking declaratory relief and ancillary orders under the Corporations Act to validate prior trading in shares and options issues, which have been made within the past few years, which were not accompanied via the issue of a cleansing notice or cleansing prospectus.
The company also entered in a supply agreement with 1300 Smiles Limited.
Separately, moving to the half-yearly results of the company. The company witnessed a rise of 61% in sales to $408,954 in December ‘18 when compared to $254,220 in December ‘17. Additionally, the company experienced a decline of 7.3% in net loss attributable to the members to $1,297,138 in December 2018, when compared to December ‘17. The net tangible asset value stood at +0.05 cps, whereas it was -0.16 cps in 30th June 2018.
The stock of IHL is trading flat at $0.019 per share on ASX (as at AEST: 12:01PM, 4 June 2019), with a market capitalisation of $11.06 million. The stock has provided a YTD return of 18.75% and delivered returns of -5% and -17.39% for the six months and one-month period, respectively.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.